Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 9/27/2024 | $16.00 | Neutral → Buy | UBS | |
| 9/9/2024 | Hold → Sell | Tudor, Pickering, Holt & Co. | ||
| 7/17/2024 | $27.00 | Neutral | Mizuho | |
| 4/10/2024 | $23.00 | Sector Weight → Overweight | KeyBanc Capital Markets | |
| 4/4/2024 | Mkt Perform | JMP Securities | ||
| 2/26/2024 | $19.00 | Market Perform | Leerink Partners | |
| 1/16/2024 | Sector Perform → Sector Underperform | Scotiabank | ||
| 12/7/2023 | $17.00 | Neutral | UBS |
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout. Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy. Below are the ratings of the most accurate analysts for three high-yielding stocks in the energy sector. CVR Energy, Inc. (NYSE:CVI) Dividend Yield: 7.88% Scotiabank analyst Paul Cheng maintained a Sector Underperform rating and cut the p
Mizuho analyst Nitin Kumar initiates coverage on CVR Energy (NYSE:CVI) with a Neutral rating and announces Price Target of $27.
Scotiabank analyst Paul Cheng maintains CVR Energy (NYSE:CVI) with a Sector Underperform and lowers the price target from $29 to $24.
RADNOR, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2024. Third Quarter Highlights: Revenue was $94.8 million, compared to $85.6 million in the third quarter of 2023, representing growth of 11%. Software revenue was $35.9 million, compared to $31.3 million in the third quarter of 2023, representing growth of 15%.Services revenue was $58.9 million, compared to $54.2 million in the third quarter of 2023, representing growth of 9%. Net loss was $1.4 million, compared to a net loss of $49.0 million in the third quarter of 2023. The $47.6 millio
Third quarter net loss attributable to CVR Energy stockholders of $124 million; EBITDA loss of $35 million; adjusted EBITDA of $63 millionThird quarter loss per diluted share of $1.24 and adjusted loss per diluted share of 50 centsCVR Energy will not pay a cash dividend for the third quarter of 2024CVR Partners announced a cash distribution of $1.19 per common unit SUGAR LAND, Texas, Oct. 28, 2024 (GLOBE NEWSWIRE) -- CVR Energy, Inc. (NYSE:CVI, "CVR Energy" or the "Company"))) today announced a net loss attributable to CVR Energy stockholders of $124 million, or $1.24 per diluted share, and an EBITDA loss of $35 million for the third quarter of 2024, compared to net income attributable to
RADNOR, Pa., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that Company management will participate in the Stephens Annual Investment Conference. Company management will present at 10:00AM CT on Thursday, November 21st, 2024. A live webcast of the event will be available on Certara's investor relations website at https://ir.certara.com and will be available for replay for at least 90 days thereafter. About CertaraCertara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutic
8-K - CVR ENERGY INC (0001376139) (Filer)
SC TO-C - CVR ENERGY INC (0001376139) (Subject)
10-Q - Certara, Inc. (0001827090) (Filer)
UBS upgraded Certara from Neutral to Buy and set a new price target of $16.00
Tudor, Pickering, Holt & Co. downgraded CVR Energy from Hold to Sell
Mizuho initiated coverage of CVR Energy with a rating of Neutral and set a new price target of $27.00
4 - EXPONENT INC (0000851520) (Issuer)
4 - EXPONENT INC (0000851520) (Issuer)
4 - EXPONENT INC (0000851520) (Issuer)
SC 13G - Certara, Inc. (0001827090) (Subject)
SC 13D/A - CVR ENERGY INC (0001376139) (Subject)
SC 13G/A - Certara, Inc. (0001827090) (Subject)
RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. "We are excited to welcome an accomplished pharmaceutical industry leader with a track record of success to Certara's Board," said William F. Feehery, PhD, CEO of Certara. "John's expertise in artificial intelligence, data science, and life science will provide immense value. We will draw on that expertise as we continue to develop and integrate transformational software and services that accelerate new medicines and increase the productivity of pharma R&
ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Cynthia Collins to the Company's Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board's compensation committee. Following her appointment, MaxCyte's total Board of Directors will increase to 10 members. "I am pleased to welcome Cynthia to MaxCyte's Board of Directors," said Mahe
RADNOR, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, has appointed Rona Anhalt as Chief Human Resources Officer and Daniel Corcoran as General Counsel. "Rona and Daniel are leaders in their fields. They have proven track records of growing teams and building high-performing businesses," said William F. Feehery Ph.D., CEO, Certara. "I'm confident they will further Certara's mission of accelerating medicines to patients through the delivery of solutions that improve the entire drug research and development process." Ms. Anhalt will drive Certara's human capital management strategy. She will lead the company's global
RADNOR, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2024. Third Quarter Highlights: Revenue was $94.8 million, compared to $85.6 million in the third quarter of 2023, representing growth of 11%. Software revenue was $35.9 million, compared to $31.3 million in the third quarter of 2023, representing growth of 15%.Services revenue was $58.9 million, compared to $54.2 million in the third quarter of 2023, representing growth of 9%. Net loss was $1.4 million, compared to a net loss of $49.0 million in the third quarter of 2023. The $47.6 millio
Third quarter net loss attributable to CVR Energy stockholders of $124 million; EBITDA loss of $35 million; adjusted EBITDA of $63 millionThird quarter loss per diluted share of $1.24 and adjusted loss per diluted share of 50 centsCVR Energy will not pay a cash dividend for the third quarter of 2024CVR Partners announced a cash distribution of $1.19 per common unit SUGAR LAND, Texas, Oct. 28, 2024 (GLOBE NEWSWIRE) -- CVR Energy, Inc. (NYSE:CVI, "CVR Energy" or the "Company"))) today announced a net loss attributable to CVR Energy stockholders of $124 million, or $1.24 per diluted share, and an EBITDA loss of $35 million for the third quarter of 2024, compared to net income attributable to
MENLO PARK, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Exponent, Inc. (NASDAQ:EXPO) today announced that its Board of Directors has declared a quarterly cash dividend of $0.28 per share of common stock to be paid on December 20, 2024 to all common stockholders of record as of December 6, 2024. Exponent has paid, and expects to continue to pay, quarterly dividends each year in March, June, September, and December. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to the final determination of Exponent's Board of Directors. "Exponent is proud to execute on our commitment to shareholders through our regular quarterly cash dividend